Advances in therapy for osteoporosis.

Robert P. Heaney

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

The current status of detection and treatment of osteoporosis is reviewed. Despite substantial advances in the past ten years, most patients with osteoporotic fractures are still not being treated for the underlying bony cause of the fracture, and most people at risk for fracture are not being offered known protective regimens. The foundation of any therapeutic program is adequate nutrition--specifically protein, calcium, phosphorus and vitamin D. Current anti-resorptive agents reduce vertebral fracture risk by 30% to 50% and teriparatide, a newly approved anabolic agent, reduces risk by up to 80+%. Effective treatments for chronic bony pain that occurs in some patients with spine fractures is affored by two minimally invasive procedures, kyphoplasty and vertebroplasty. Some of these chronically painful fractures represent instances of previously unrecognized non-union, and in them low-pressure vertebroplasty produces prompt and lasting relief. Fracture risk reductions with current anti-resorptive agents are at least twice as great as can be explained by drug effects on bone mass. Moreover, risk is reduced within a few months of starting therapy. These observations focus attention on bone remodeling and point to the need for improvement of biomarker technology, since it seems likely that reduction in remodeling activity underlies much of the fracture risk reduction and can therefore be used to monitor therapy.

Original languageEnglish
Pages (from-to)93-99
Number of pages7
JournalClinical Medicine and Research
Volume1
Issue number2
StatePublished - Apr 2003

Fingerprint

Osteoporosis
Vertebroplasty
Fracture Fixation
Risk Reduction Behavior
Kyphoplasty
Teriparatide
Therapeutics
Anabolic Agents
Osteoporotic Fractures
Bone Remodeling
Vitamin D
Chronic Pain
Phosphorus
Spine
Biomarkers
Calcium
Technology
Pressure
Bone and Bones
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Community and Home Care

Cite this

Advances in therapy for osteoporosis. / Heaney, Robert P.

In: Clinical Medicine and Research, Vol. 1, No. 2, 04.2003, p. 93-99.

Research output: Contribution to journalReview article

Heaney, RP 2003, 'Advances in therapy for osteoporosis.', Clinical Medicine and Research, vol. 1, no. 2, pp. 93-99.
Heaney, Robert P. / Advances in therapy for osteoporosis. In: Clinical Medicine and Research. 2003 ; Vol. 1, No. 2. pp. 93-99.
@article{d3f72396a4a44d9497f4600f3590d674,
title = "Advances in therapy for osteoporosis.",
abstract = "The current status of detection and treatment of osteoporosis is reviewed. Despite substantial advances in the past ten years, most patients with osteoporotic fractures are still not being treated for the underlying bony cause of the fracture, and most people at risk for fracture are not being offered known protective regimens. The foundation of any therapeutic program is adequate nutrition--specifically protein, calcium, phosphorus and vitamin D. Current anti-resorptive agents reduce vertebral fracture risk by 30{\%} to 50{\%} and teriparatide, a newly approved anabolic agent, reduces risk by up to 80+{\%}. Effective treatments for chronic bony pain that occurs in some patients with spine fractures is affored by two minimally invasive procedures, kyphoplasty and vertebroplasty. Some of these chronically painful fractures represent instances of previously unrecognized non-union, and in them low-pressure vertebroplasty produces prompt and lasting relief. Fracture risk reductions with current anti-resorptive agents are at least twice as great as can be explained by drug effects on bone mass. Moreover, risk is reduced within a few months of starting therapy. These observations focus attention on bone remodeling and point to the need for improvement of biomarker technology, since it seems likely that reduction in remodeling activity underlies much of the fracture risk reduction and can therefore be used to monitor therapy.",
author = "Heaney, {Robert P.}",
year = "2003",
month = "4",
language = "English",
volume = "1",
pages = "93--99",
journal = "Clinical Medicine and Research",
issn = "1539-4182",
publisher = "Marshfield Clinic",
number = "2",

}

TY - JOUR

T1 - Advances in therapy for osteoporosis.

AU - Heaney, Robert P.

PY - 2003/4

Y1 - 2003/4

N2 - The current status of detection and treatment of osteoporosis is reviewed. Despite substantial advances in the past ten years, most patients with osteoporotic fractures are still not being treated for the underlying bony cause of the fracture, and most people at risk for fracture are not being offered known protective regimens. The foundation of any therapeutic program is adequate nutrition--specifically protein, calcium, phosphorus and vitamin D. Current anti-resorptive agents reduce vertebral fracture risk by 30% to 50% and teriparatide, a newly approved anabolic agent, reduces risk by up to 80+%. Effective treatments for chronic bony pain that occurs in some patients with spine fractures is affored by two minimally invasive procedures, kyphoplasty and vertebroplasty. Some of these chronically painful fractures represent instances of previously unrecognized non-union, and in them low-pressure vertebroplasty produces prompt and lasting relief. Fracture risk reductions with current anti-resorptive agents are at least twice as great as can be explained by drug effects on bone mass. Moreover, risk is reduced within a few months of starting therapy. These observations focus attention on bone remodeling and point to the need for improvement of biomarker technology, since it seems likely that reduction in remodeling activity underlies much of the fracture risk reduction and can therefore be used to monitor therapy.

AB - The current status of detection and treatment of osteoporosis is reviewed. Despite substantial advances in the past ten years, most patients with osteoporotic fractures are still not being treated for the underlying bony cause of the fracture, and most people at risk for fracture are not being offered known protective regimens. The foundation of any therapeutic program is adequate nutrition--specifically protein, calcium, phosphorus and vitamin D. Current anti-resorptive agents reduce vertebral fracture risk by 30% to 50% and teriparatide, a newly approved anabolic agent, reduces risk by up to 80+%. Effective treatments for chronic bony pain that occurs in some patients with spine fractures is affored by two minimally invasive procedures, kyphoplasty and vertebroplasty. Some of these chronically painful fractures represent instances of previously unrecognized non-union, and in them low-pressure vertebroplasty produces prompt and lasting relief. Fracture risk reductions with current anti-resorptive agents are at least twice as great as can be explained by drug effects on bone mass. Moreover, risk is reduced within a few months of starting therapy. These observations focus attention on bone remodeling and point to the need for improvement of biomarker technology, since it seems likely that reduction in remodeling activity underlies much of the fracture risk reduction and can therefore be used to monitor therapy.

UR - http://www.scopus.com/inward/record.url?scp=27744483578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744483578&partnerID=8YFLogxK

M3 - Review article

VL - 1

SP - 93

EP - 99

JO - Clinical Medicine and Research

JF - Clinical Medicine and Research

SN - 1539-4182

IS - 2

ER -